Economics of Innovation
Optimal innovation balances willingness and ability to pay with the benefits of future R&D. Our wide-ranging programme aims to promote innovation in health care, increase our understanding of its value, and encourage R&D. New models of innovation should streamline development, reduce costs, and speed patient benefit.
An Insurance Framework for Funding New Antibiotics
22 September 2017
A new paper sets out an insurance model as part of a global solution to incentivise R&D for new antibiotics to tackle multi-drug resistance. It offers…
OHE at iHEA 2017: Presentations
8 August 2017
The presentations delivered by OHE at the iHEA congress, July 2017, are available in this post.
OHE Lunchtime Seminar: How Cost-Effective are New Cancer Drugs in the U.S.?
2 August 2017
On Tuesday 19th September 2017, Professor Frank Lichtenberg from Columbia University will lead an OHE Lunchtime Seminar on the topic of: How cost-effective are new cancer…
OHE at HTAi Rome
12 July 2017
The presentations delivered by OHE at the HTAi Annual Meeting, June 2017, are available in this post.
Postdoctoral Position in The Economics of Life Sciences R&D
27 June 2017
The Structural Genomics Consortium Oxford, University of Oxford, in collaboration with OHE (Prof Adrian Towse) and Dr Jorge Mestre-Ferrandiz, is recruiting for a Postdoctoral Position in…
Professor Dame Sally Davies: Ten Years of the NIHR: Achievements and Challenges for the Next Decade
15 June 2017
In November 2016 Professor Dame Sally Davies delivered the 23rd OHE Annual Lecture on the topic of: Ten Years of the NIHR: Achievements and Challenges for…
Assessing the Value of New Antibiotics: Additional Elements of Value for Health Technology Assessment Decisions
30 May 2017
Without new antibiotics, more patients will die from previously treatable infections. A key issue is how the value of antibiotics can be appropriately assessed by payers…
New Publication: ‘Macro’ Evaluation of the NIHR Oxford Biomedical Research Centre
22 May 2017
OHE and RAND Europe were commissioned by the Oxford BRC to undertake a programme of top-down evaluations of aspects of the impact of the BRC. This…
Incentives for New Drugs and Vaccines to Tackle Anti-Microbial Resistance
16 May 2017
Resistance to antibiotics is growing. Additional R&D is required. Both Transferable Intellectual Property Rights and Market Entry Rewards should be explored for use in Europe as…